within Pharmacolibrary.Drugs.ATC.G;

model G01AX17
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 8.183333333333333e-05,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.056600000000000004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G01AX17</td></tr><td>route:</td><td>vaginal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used primarily in the form of a vaginal ring to prevent HIV-1 infection in women. The drug is designed for topical use to achieve high local concentrations and minimal systemic exposure. Dapivirine vaginal rings have received a positive scientific opinion from the European Medicines Agency and are recommended by the World Health Organization for HIV prevention in women.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult women, post-menopausal and reproductive age, enrolled in clinical trials assessing dapivirine vaginal ring (25 mg), steady-state achieved after repeated monthly administration.</p><h4>References</h4><ol><li><p>das Neves, J, et al., &amp; Sarmento, B (2014). Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice. <i>Pharmaceutical research</i> 31(7) 1834–1845. DOI:<a href=&quot;https://doi.org/10.1007/s11095-013-1287-x&quot;>10.1007/s11095-013-1287-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24449442/&quot;>https://pubmed.ncbi.nlm.nih.gov/24449442</a></p></li><li><p>Robinson, JA, et al., &amp; Hendrix, CW (2017). Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). <i>AIDS research and human retroviruses</i> 33(4) 339–346. DOI:<a href=&quot;https://doi.org/10.1089/AID.2016.0040&quot;>10.1089/AID.2016.0040</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27809557/&quot;>https://pubmed.ncbi.nlm.nih.gov/27809557</a></p></li><li><p>Achilles, SL, et al., &amp; Chen, BA (2024). Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings. <i>PloS one</i> 19(6) e0304552–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0304552&quot;>10.1371/journal.pone.0304552</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38838028/&quot;>https://pubmed.ncbi.nlm.nih.gov/38838028</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G01AX17;
